Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
May 10, 2022
– 2H 2022 clinical data readout on track for patients with Dravet syndrome who received multiple doses of STK-001 (30mg) in P ...Stoke Therapeutics Presents New In-Vivo Data That Demonstrated Dose-Related Target Engagement and OPA1 Protein Upre ...
May 2, 2022
– Data presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting support the Company’s work ...Stoke Therapeutics to Present at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meetin ...
April 7, 2022
– New preclinical data support the ongoing preclinical development of STK-002 for the treatment of autosomal dominant optic a ...Stoke Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
April 5, 2022
BEDFORD, Mass. --(BUSINESS WIRE)--Apr. 5, 2022-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated t ...Stoke Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates
March 10, 2022
– Enrollment and dosing ongoing in the Phase 1/2a MONARCH and ADMIRAL studies of STK-001 in children and adolescents with Dra ...Stoke Therapeutics to Participate in the Cowen 42nd Annual Health Care Conference
February 28, 2022
BEDFORD, Mass. --(BUSINESS WIRE)--Feb. 28, 2022-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated ...Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Se ...
January 10, 2022
– Establishes co-development and co-commercialization agreement for Stoke’s SYNGAP1 preclinical program – Acadia receives exc ...Stoke Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 4, 2022
BEDFORD, Mass. --(BUSINESS WIRE)--Jan. 4, 2022-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated t ...